Myomo (NYSEAMERICAN:MYO – Get Free Report) is projected to announce its earnings results before the market opens on Monday, March 10th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $9.90 million for the quarter. Investors interested in listening to the company’s conference call can do so using this link.
Myomo Stock Performance
MYO opened at $4.60 on Friday. The company has a market capitalization of $139.15 million, a P/E ratio of -20.00 and a beta of 1.68. Myomo has a 1-year low of $2.51 and a 1-year high of $7.17.
Analysts Set New Price Targets
A number of equities research analysts recently weighed in on MYO shares. HC Wainwright restated a “buy” rating and issued a $7.50 price target on shares of Myomo in a report on Wednesday, November 13th. Ascendiant Capital Markets increased their target price on Myomo from $8.50 to $9.00 and gave the company a “buy” rating in a report on Tuesday, November 12th. Finally, Craig Hallum increased their target price on Myomo from $7.00 to $9.00 and gave the company a “buy” rating in a report on Friday, December 13th.
Myomo Company Profile
Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living.
Featured Stories
- Five stocks we like better than Myomo
- Low PE Growth Stocks: Unlocking Investment Opportunities
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
- Why is the Ex-Dividend Date Significant to Investors?
- 3 Stocks to Buy While Others Stay on the Sidelines
- What is a Death Cross in Stocks?
- MarketBeat Week in Review – 03/03 – 03/07
Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with MarketBeat.com's FREE daily email newsletter.